Latest Breaking News On - Roberth uhl - Page 1 : comparemela.com

HARPOON THERAPEUTICS ANNOUNCES FIRST PATIENTS WITH SMALL CELL LUNG CANCER DOSED IN HPN328 COMBINATION COHORT

SOUTH SAN FRANCISCO - Harpoon Therapeutics, Inc. , a clinical-stage immuno-oncology company developing novel T cell engagers, today announced dosing of the first patients with small cell lung cancer .

Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort

Harpoon Therapeutics (HARP) Provides an Update on the HPN217 Development and Deal with AbbVie (ABBV)

Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has notified the company that it will not exercise the exclusive license option of the parties’ Development and Option Agreement in connection with Harpoon’s HPN217 program, which targets B cell maturation antigen, or BCMA. ​The Agreement, which will terminate effective October 12, 2023, g

Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie - Harpoon Therapeutics (NASDAQ:HARP)

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has